DSGN
NASDAQ · Biotechnology
Design Therapeutics Inc
$10.63
+0.29 (+2.80%)
Analyst Consensus
Strong Buy
13
Analysts
Moderate
Coverage
Price Target
Analyst Price Target
+454.6% upside
Low Target
$40.84
Average Target
$58.95
High Target
$77.34
Current Price
$10.63
Current
$10.63
$10.63
Target
$58.95
$58.95
$40.84
$58.95 avg
$77.34
Scenario Analysis
Bear Case
$40.84
284.2%
Low target
Base Case
$58.95
+454.6%
Avg target
Bull Case
$77.34
+627.6%
High target
Risk/Reward
2.2x
Favorable
Price in Context
52-Week High
$17.25
-38.4% from high
52-Week Low
$6.16
+72.6% from low
Target vs 52W High
$58.95
+241.7% vs high
Next Earnings Report
Nov 11, 2026
4d
until earnings
EPS Est: $-0.35
Earnings in 4 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
| Stock | Consensus | Analysts | Buy % | Target | Upside |
|---|---|---|---|---|---|
| ABBV | Strong Buy | 39 | 82% | $257.58 | -10.6% |
| AMGN | Hold | 42 | 43% | $190.87 | -58.5% |
| GILD | Strong Buy | 37 | 81% | $362.68 | +116.4% |
| VRTX | Strong Buy | 39 | 82% | $438.34 | -19.2% |
| MRNA | Hold | 31 | 35% | $149.45 | -38.1% |
| REGN | Buy | 37 | 70% | $76.80 | -91.5% |
| NTRA | Strong Buy | 30 | 90% | $142.91 | -60.7% |
| RVMD | Strong Buy | 29 | 93% | $114.11 | -35.8% |